WO2008152448A3 - Streptococcus proteins, and their use in vaccination - Google Patents
Streptococcus proteins, and their use in vaccination Download PDFInfo
- Publication number
- WO2008152448A3 WO2008152448A3 PCT/IB2007/004637 IB2007004637W WO2008152448A3 WO 2008152448 A3 WO2008152448 A3 WO 2008152448A3 IB 2007004637 W IB2007004637 W IB 2007004637W WO 2008152448 A3 WO2008152448 A3 WO 2008152448A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pho3
- pho1
- present
- pho2
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Group B Streptococcus (GBS) infection. The present invention is also directed toward a composition comprising two or more of polypeptides, wherein said polypeptide comprises an amino acid sequence at least 80% identical to the reference amino acid sequence selected from the group consisting of Pho1-13, Pho1-14, Pho1-5, Pho3-3 (pho1-7), Pho2-10, Pho2-15, Pho2-2 (ME:P22), Pho3-14, Pho3-17, Pho3-18, Pho3-1 (ME:P31), Pho3-21, Pho3-22, Pho3-23, Pho3-24, Pho3- 29, Pho3-50, MS4, MS11, MS16, MS14, MS10(NP GAP, ME:NAP), PBP, pho 3-9, OCT, PGK, and NPGAP, a fragment, variant, analog, or derivative thereof, wherein said polypeptide is recognizable by an antibody preparation that specifically binds to a polypeptide consisting of the reference amino acid sequence. In some embodiments, the present invention is directed to a method of inducing an immune response in a host comprising administering to said host an effective amount of the composition of the present invention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07874553A EP2104512A2 (en) | 2006-12-21 | 2007-12-21 | Streptococcus proteins, and their use in vaccination |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87615606P | 2006-12-21 | 2006-12-21 | |
US60/876,156 | 2006-12-21 | ||
US98511107P | 2007-11-02 | 2007-11-02 | |
US60/985,111 | 2007-11-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008152448A2 WO2008152448A2 (en) | 2008-12-18 |
WO2008152448A3 true WO2008152448A3 (en) | 2009-05-22 |
Family
ID=40130254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/004637 WO2008152448A2 (en) | 2006-12-21 | 2007-12-21 | Streptococcus proteins, and their use in vaccination |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2104512A2 (en) |
WO (1) | WO2008152448A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102695523A (en) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | Combination vaccines against respiratory tract diseases |
BR112012009309B1 (en) * | 2009-10-19 | 2021-10-05 | Intervet International B.V | COMBINED VACCINE, USE OF MICRO-ORGANISMS CELLS, METHOD FOR THE PREPARATION OF A COMBINED VACCINE, AND, KIT OF PARTS |
CN103648489A (en) * | 2011-05-11 | 2014-03-19 | 儿童医疗中心有限公司 | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
CA2900008A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
AU2018243910A1 (en) | 2017-03-28 | 2019-11-14 | The Children's Medical Center Corporation | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
KR20200041311A (en) | 2017-06-23 | 2020-04-21 | 노소코미얼 백신 코포레이션 | Immunogenic composition |
JP2021535921A (en) | 2018-09-12 | 2021-12-23 | アフィニバックス、インコーポレイテッド | Multivalent pneumococcal vaccine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037646A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Group b streptococcus proteins, and their use |
WO2000037490A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Outer surface proteins, their genes, and their use |
WO2002072623A1 (en) * | 2001-03-09 | 2002-09-19 | Microscience Limited | Genes and proteins, and their use |
WO2005028618A2 (en) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Immunogenic compositions for streptococcus agalactiae |
-
2007
- 2007-12-21 EP EP07874553A patent/EP2104512A2/en not_active Withdrawn
- 2007-12-21 WO PCT/IB2007/004637 patent/WO2008152448A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037646A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Group b streptococcus proteins, and their use |
WO2000037490A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Outer surface proteins, their genes, and their use |
WO2002072623A1 (en) * | 2001-03-09 | 2002-09-19 | Microscience Limited | Genes and proteins, and their use |
WO2005028618A2 (en) * | 2003-09-15 | 2005-03-31 | Chiron Corporation | Immunogenic compositions for streptococcus agalactiae |
Non-Patent Citations (1)
Title |
---|
MARTIN J.G. HUGHES ET AL.: "Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphatase fusions", FEMS MICROBIOLOGY LETTERS, vol. 222, 2003, pages 263 - 271, XP002514097 * |
Also Published As
Publication number | Publication date |
---|---|
EP2104512A2 (en) | 2009-09-30 |
WO2008152448A2 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008152448A3 (en) | Streptococcus proteins, and their use in vaccination | |
Watkins et al. | Safe recombinant outer membrane vesicles that display M2e elicit heterologous influenza protection | |
McNeela et al. | A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery | |
Sambhara et al. | Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function | |
Roberts et al. | A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins | |
JP2015500827A5 (en) | ||
JP2012523246A5 (en) | ||
JP2012504660A5 (en) | ||
JP2004535187A (en) | Mutant forms of cholera holotoxin as adjuvants | |
Novotny et al. | Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization | |
Nussbaum et al. | Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components | |
CA2739581A1 (en) | Compositions and methods related to bacterial eap, emp, and/or adsa proteins | |
NO20004972D0 (en) | Derivatives of pneumococcal choline binding proteins | |
WO2001045639A3 (en) | Methods for protecting against lethal infection with bacillus anthracis | |
Naito et al. | The protective effects of nasal PcrV‐CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia | |
KR20070017348A (en) | Antigen-drug vehicle enabling transmucosal, and transdermal administration and method of inducing mucosal immunity, mucosal vaccine and dds using the same | |
Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
Yan | Salivary IgA enhancement strategy for development of a nasal-spray anti-caries mucosal vaccine | |
Michalek et al. | A vaccine against dental caries: an overview | |
JP2015529677A5 (en) | ||
Mifsud et al. | Reducing the impact of influenza‐associated secondary pneumococcal infections | |
Cheong et al. | Epigallocatechin-3-gallate as a novel vaccine adjuvant | |
JP5661744B2 (en) | Polypeptides from enterococci and their use for vaccination | |
NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
Virelizier et al. | The role of humoral immunity in host defence against influenza A infection in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07874553 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007874553 Country of ref document: EP |